Recruiting × Waldenstrom Macroglobulinemia × 90 days × Clear all Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Recruiting
1,000 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
36 enrolled
CAN3001
Phase 3 Recruiting
700 enrolled
MK-1026-003
Phase 2 Recruiting
490 enrolled
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Phase 2 Recruiting
92 enrolled
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
Phase 2 Recruiting
14 enrolled
ZEBRA
Phase 2 Recruiting
55 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled
Epcoritamab in Previously Treated WM
Phase 2 Recruiting
20 enrolled
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Recruiting
111 enrolled
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2 Recruiting
180 enrolled
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
Recruiting
100 enrolled
PRAME
Recruiting
1,000 enrolled
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 Recruiting
60 enrolled
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 Recruiting
98 enrolled
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Recruiting
10,000 enrolled
RUBIN
Recruiting
2,950 enrolled